PMID- 25850013
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150408
LR  - 20200929
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 8
IP  - 2
DP  - 2015 Apr 2
TI  - Edaravone enhances brain-derived neurotrophic factor production in the ischemic 
      mouse brain.
PG  - 176-85
LID - 10.3390/ph8020176 [doi]
AB  - Edaravone, a clinical drug used to treat strokes, protects against neuronal cell 
      death and memory loss in the ischemic brains of animal models through its 
      antioxidant activity. In the present study, we subcutaneously administrated 
      edaravone to mice (3 mg/kg/day) for three days immediately after bilateral common 
      carotid artery occlusion, and revealed through an immunohistochemical analysis 
      that edaravone (1) accelerated increases in the production of brain-derived 
      neurotrophic factor (BDNF) in the hippocampus; (2) increased the number of 
      doublecortin-positive neuronal precursor cells in the dentate gyrus subgranular 
      zone; and (3) suppressed the ischemia-induced inactivation of 
      calcium-calmodulin-dependent protein kinase II in the hippocampus. We also 
      revealed through a Western blotting analysis that edaravone (4) induced the 
      phosphorylation of cAMP response element-binding (CREB), a transcription factor 
      that regulates BDNF gene expression; and (5) induced the phosphorylation of 
      extracellular signal-regulated kinases 1/2, an upstream signal factor of CREB. 
      These results suggest that the neuroprotective effects of edaravone following 
      brain ischemia were mediated not only by the elimination of oxidative stress, but 
      also by the induction of BDNF production.
FAU - Okuyama, Satoshi
AU  - Okuyama S
AD  - Department of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, 
      Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. 
      sokuyama@cc.matsuyama-u.ac.jp.
FAU - Morita, Mayu
AU  - Morita M
AD  - Department of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, 
      Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. 
      lmv_mayu_laulea@yahoo.co.jp.
FAU - Sawamoto, Atsushi
AU  - Sawamoto A
AD  - Department of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, 
      Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. 
      46140018@cc.matsuyama-u.ac.jp.
FAU - Terugo, Tsukasa
AU  - Terugo T
AD  - Department of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, 
      Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. 
      66140105@cc.matsuyama-u.ac.jp.
FAU - Nakajima, Mitsunari
AU  - Nakajima M
AD  - Department of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, 
      Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. 
      mnakajim@cc.matsuyama-u.ac.jp.
FAU - Furukawa, Yoshiko
AU  - Furukawa Y
AD  - Department of Pharmaceutical Pharmacology, College of Pharmaceutical Sciences, 
      Matsuyama University, 4-2 Bunkyo-cho, Matsuyama, Ehime 790-8578, Japan. 
      furukawa@cc.matsuyama-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20150402
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC4491654
EDAT- 2015/04/08 06:00
MHDA- 2015/04/08 06:01
PMCR- 2015/06/01
CRDT- 2015/04/08 06:00
PHST- 2015/02/24 00:00 [received]
PHST- 2015/03/24 00:00 [revised]
PHST- 2015/03/26 00:00 [accepted]
PHST- 2015/04/08 06:00 [entrez]
PHST- 2015/04/08 06:00 [pubmed]
PHST- 2015/04/08 06:01 [medline]
PHST- 2015/06/01 00:00 [pmc-release]
AID - ph8020176 [pii]
AID - pharmaceuticals-08-00176 [pii]
AID - 10.3390/ph8020176 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2015 Apr 2;8(2):176-85. doi: 10.3390/ph8020176.